India's bioeconomy has experienced significant growth, increasing from USD 166 billion in 2024 to USD 195 billion in 2025. This expansion is driven by diverse industries including biopharmaceuticals ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

The Minister credited BIRAC as a key catalyst in translating scientific research into commercially viable products.

While the deal makes strategic sense, integrating two distinct businesses and delivering profitability ahead of a potential ...

Biotechnology – and its potential space in South Dakota's economy – has been slowly developing nationwide for decades. With recent advancements in the state like the University of South Dakota ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced the appointment of John A. Orwin as Chair of its Board of Directors. Mr. Orwin ...

Redmile Group increased its Nurix Therapeutics holding by 4,415,514 shares; the estimated trade value was $63.43 million based on quarterly average pricing. Meanwhile, the quarter-end position value ...

The Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday. The news is the ...

The Food and Drug Administration has refused to start a review of Moderna's application for its experimental flu shot, the company said. It's another sign of the Trump administration's influence on ...

Veradermics, a small biotechnology company looking to develop drugs for hair loss, enjoyed a stunning debut on Wall Street Wednesday. And that’s no bald-faced lie. (Sorry. Not sorry.) Shares of ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind Rogaine—is well coiffed to tap into the increasingly lush opportunity for hair ...